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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.027Aberrant focal adhesion turnover is centrally involved inpodocyte actin cytoskeletondisorganizationand foot
process effacement. The structural and dynamic integrity of focal adhesions is orchestrated by multiple cell
signaling molecules, including glycogen synthase kinase 3b (GSK3b), a multitasking kinase lately identiﬁed
as a mediator of kidney injury. However, the role of GSK3b in podocytopathy remains obscure. In doxorubicin
(Adriamycin)-injured podocytes, lithium, a GSK3b inhibitor and neuroprotective mood stabilizer, obliterated
the accelerated focal adhesion turnover, rectiﬁed podocyte hypermotility, and restored actin cytoskeleton
integrity. Mechanistically, lithium counteracted the doxorubicin-elicited GSK3b overactivity and the
hyperphosphorylation andoveractivationof paxillin, a focal adhesioneassociated adaptor protein.Moreover,
forced expression of a dominant negative kinase dead mutant of GSK3b highly mimicked, whereas ectopic
expression of a constitutively active GSK3b mutant abolished, the effect of lithium in doxorubicin-injured
podocytes, suggesting that the effect of lithium is mediated, at least in part, through inhibition of GSK3b.
Furthermore, paxillin interacted with GSK3b and served as its substrate. In mice with doxorubicin ne-
phropathy, a single low dose of lithium ameliorated proteinuria and glomerulosclerosis. Consistently, lithium
therapy abrogated GSK3b overactivity, blunted paxillin hyperphosphorylation, and reinstated actin cyto-
skeleton integrity in glomeruli associated with an early attenuation of podocyte foot process effacement.
Thus, GSK3b-modulated focal adhesion dynamics might serve as a novel therapeutic target for podocytop-
athy. (Am J Pathol 2014, 184: 2742e2756; http://dx.doi.org/10.1016/j.ajpath.2014.06.027)Supported in part by NIH grant R01DK092485 (R.G.), the China
973 program 2012CB517600 (Z.L.), and the International Society of
Nephrology Sister Renal Center Trio Program.
Disclosures: None declared.Glomerular visceral epithelial cells or podocytes are a core
structural constituent of the glomerular ﬁltration barrier, with
elaborate interdigitating foot processes that envelop the
capillaries of the glomeruli in the kidney, control glomerular
permselectivity, and prevent protein in the bloodstream from
leaking into the urine.1e4 Converging evidence suggests that
the podocytic ﬁlter barrier is not static but a highly dynamic
structure that is regulated via the motility of podocyte foot
processes.5e7 The molecular basis of foot process motility
lies in the constant dynamics of the molecular machinery
that sustains the foot process architecture.5e7 Actin is thestigative Pathology.
.principal component of the cytoskeletal machinery of foot
processes and forms a subcortical network of branched ﬁla-
ments as well as bundled ﬁlaments that run longitudinally
through the processes with contractility.8 Actin exists in foot
processes in a state of dynamic equilibrium between assem-
bly and disassembly, which is important for maintaining the
GSK3b Regulates Podocyte FA Dynamicshomeostasis of the glomerular ﬁltration barrier. In response
to various pathogenic mediators, including oxidative stress,
circulating permeability factors, and nephrotoxins such as
doxorubicin (Adriamycin), the parallel actin bundles depo-
lymerize, resulting in foot process effacement, a pathologic
hallmark of podocyte injury and dysfunction.9e13
Focal adhesions (FAs), by which cells are anchored to the
extracellular matrix, are a crucial determinant of actin cyto-
skeleton integrity and cell motility.14,15 Molecules from FA
structures connect the extracellular matrix to bundles of actin
ﬁlaments, enabling the growing actin network to push the
plasma membrane and the contractile stress ﬁbers to pull the
cell body, corresponding to protrusive and retractive activ-
ities.14,16 Dynamic turnover of FAs is indispensable for
constant motility and reorganization of cell edges that man-
ifest as boundary curvature waves.17 A cycle of cellular
boundary motion commences with the formation of nascent
adhesions, which initiate actin assembly and, thus, allow the
growing actin network to push the cell protrusion forward.
The nascent adhesion or focal complex, a precursor of the
FA, is smaller in size, with weaker adhesive force and rapid
turnover.18,19 Subsequently, nascent adhesions will either
disassemble rapidly or mature to be FAs. The FAs usually
contain multiple structural and regulatory molecules, among
which paxillin acts as a pivotal adaptor protein to provide
docking sites for cytoskeletons and to recruit FA regulators
that control actin dynamics and FA stability.20 The rate of FA
turnover determines cell motility and governs the podocyte
foot process dynamics. Consistently, targeted manipulation
of FA turnover in podocytes by enhancing or intercepting the
activity of FA regulatory molecules incurred foot process
effacement and podocyte dysfunction.21e23
Glycogen synthase kinase 3b (GSK3b), a well-conserved
and ubiquitously expressed serine/threonine protein kinase,
plays a key role in the regulation of cytoskeleton organization
and cellular motility.24,25 Indeed, inhibition of GSK3b has
been found to reduce cell motility in multiple cells, including
vascular smooth muscle cells,26 glioma cells,27 gastric cancer
cells,28 and renal tubular epithelial cells.29 In the kidney,
GSK3b has lately been implicated in acute kidney injury
and repair.30 However, its role in podocyte injury and foot
process cytoskeletal disarrangement remains unknown.
This study examined the role of GSK3b in a model of
hypermotility-associated podocytopathy induced by doxo-
rubicin injury in vivo and in vitro. The potential intervention
effect of GSK3b blockade by a single low dose of lithium, a
selective GSK3b inhibitor and US Food and Drug Admin-
istrationeapproved mood stabilizer, on podocyte motility
and dysfunction was accordingly delineated.
Materials and Methods
Cell Culture and Transient Transfection
Conditionally immortalized mouse podocytes in culture were
a gift from Dr. Stuart Shankland (University of Washington,The American Journal of Pathology - ajp.amjpathol.orgSeattle, WA).31 The cells between passages 21 to 25 were
used. Podocytes were cultured in RPMI 1640 medium (Life
Technologies, Grand Island, NY) supplemented with 10%
fetal bovine serum (Life Technologies), 0.075% sodium bi-
carbonate (Sigma-Aldrich, St. Louis, MO), 0.075% sodium
pyruvate (Sigma-Aldrich), 100 U/mL of penicillin, and 100
mg/mL of streptomycin (Life Technologies) in a humidiﬁed
incubator with 5% CO2. The cells were cultured at 33C with
50 U/mL of recombinant mouse interferon-g (Millipore,
Billerica, MA) on collagen-coated Petri dishes. The cells were
transferred to 37C incubators without interferon-g to induce
differentiation, which took 14 days, and then were treated
with doxorubicin (0.25 mg/mL; Sigma-Aldrich) and/or lithium
chloride (10 mmol/L; Sigma-Aldrich). Podocytes were
cultured under permissive conditions (33C) and were pre-
pared for immunoblot analysis after sodium chloride (10
mmol/L) treatment for 24 hours. Subcultures of the immor-
talizedmouse podocytes weremaintained under nonpermissive
conditions (37C) to induce differentiation for 14 days and then
were treated with lithium chloride (10 or 20 mmol/L) for 24 or
48 hours. As control, cells were treated with sodium chloride
(10 mmol/L) for 24 hours. Cells were subsequently collected
and prepared for Western blot analysis and immunohisto-
chemical staining. The expression vectors encoding the
constitutively active GSK3b mutant (S9A-GSK3b-HA/
pcDNA3), kinase-dead GSK3b mutant (KD-GSK3b-HA/
pcDNA3), and wild-type GSK3b (WT-GSK3b-HA/pcDNA3)
were a gift from Dr. Gail V.W. Johnson (University of
Alabama at Birmingham, Birmingham, AL).32 The vector
encoding green ﬂuorescent proteinepaxillin was a gift fromDr.
Luc Sabourin (OttawaHospital Research Institute, Ottawa, ON,
Canada).33 Podocytes were transfected by using Lipofectamine
2000 reagent (Life Technologies) as previously described.34
Cell Migration Assay
Conﬂuent monolayers of differentiated podocytes were
scraped with a 10-mL pipette after different treatments.
Images of the same area were acquired at indicated time
points using an inverted microscope and were analyzed
using the ImageJ version 1.48 (NIH, Bethesda, MD)
image processing program. The percentage of cell
migration area was calculated as
ðArea0 hour Areaindicated timeÞ=Area0 hour ð1Þ
Time-Lapse Fluorescence Microscopy
Podocytes transected with green ﬂuorescent proteine
paxillin were subjected to different treatments and placed in
a heating chamber (37C) on the stage of a time-lapse
ﬂuorescence microscope (Axiovert; Zeiss, Cologne, Ger-
many). Images were taken at 2-minute intervals. The FA
turnover rate was calculated using the Focal Adhesion
Analysis Server web tool (http://faas.bme.unc.edu, last
accessed October 7, 2013), as described previously.352743
Xu et alWestern Immunoblot Analysis
Cultured cells were lyzed and animal tissues homogenized in
radioimmunoprecipitation assay buffer supplemented with
protease inhibitors and samples were processed for immu-
noblot analysis. The antibodies against paxillin, GSK3b,
p-GSK3b (S9), synaptopodin, and glyceraldehyde-3-
phosphate dehydrogenase were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), and those against paxillin,
phosphorylated paxillin (S126), and nephrin were acquired
from Cell Signaling Technology Inc. (Danvers, MA) and Pro-
gen Biotechnik GmbH (Heidelberg, Germany), respectively.
Animal Experiment Design
Animal studies were approved by the Rhode Island Hospital
Animal Care and Use Committee, and they conform to the
US Department of Agriculture regulations and the NIH’s
Guide for the Care and Use of Laboratory Animals.36 Male
BALB/c mice weighing 20 to 25 g and aged 8 weeks were
randomly assigned to the following treatments. A single dose
of lithium chloride (40 mg/kg) or an equal molar amount (1
mEq/kg) of sodium chloride as saline was given via i.p. in-
jection on day 0. Doxorubicin (10 mg/kg) or an equal volume
of vehicle was given as a tail vein injection 6 hours later.
Groups control, LiCl, NaCl þ ADR, and LiCl þ ADR refer
to sodium chloride þ vehicle, lithium chloride þ vehicle,
sodium chloride þ doxorubicin, and lithium chloride þ
doxorubicin treatments, respectively. Spot urine was col-
lected on postinjury days 0, 1, 3, 5, 7, 10, and 14. Mice were
sacriﬁced on days 3, 7, and 14. Six mice were randomly
assigned to each group for each observed time point.
Urine Analyses
To discern the protein compositions in urine, equal amounts
of urine samples were subjected to SDS-PAGE followed by
Coomassie Blue (Sigma-Aldrich) staining. Urine albumin
concentration was measured using a mouse albumin
enzyme-linked immunosorbent assay quantitation kit
(Bethyl Laboratories Inc., Montgomery, TX). Urine creati-
nine concentration was measured by a creatinine assay kit
(BioAssay Systems, Hayward, CA).
Morphologic Studies
Formalin-ﬁxed kidneys were embedded in parafﬁn and pre-
pared sections (3-mm thick). For general histologic analysis,
sections were processed for periodic acideSchiff staining.
The morphologic features of all the sections were assessed
by a single observer (W.X.) in a blinded manner. A semi-
quantitative glomerulosclerosis score was used to evaluate
the degree of glomerulosclerosis. The severity of sclerosis for
each glomerulus was graded from 0 to 4 as follows: 0 repre-
sents no lesions; 1, sclerosis of<25% of the glomerulus; and
2, 3, and 4, sclerosis of 25% to 50%, >50% to 75%, and2744>75% of the glomerulus, respectively. A whole-kidney
average glomerulosclerosis score was obtained by aver-
aging scores from all glomeruli on one section.
Immunoﬂuorescence Staining
Podocytes or cryosections of kidneys were ﬁxed with
4% paraformaldehyde (Sigma-Aldrich), permeabilized, and
stained with primary antibodies against paxillin, GSK3b, and
synaptopodin, followed by Alexa ﬂuorophoreeconjugated
secondary antibody staining (Life Technologies). Filamen-
tous actin (F-actin) was stained by rhodamine phalloidin
(Cytoskeleton Inc., Denver, CO). Finally, cells were coun-
terstained with DAPI, mounted with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA), and visu-
alized using a ﬂuorescence microscope. As a negative con-
trol, the primary antibody was replaced by preimmune serum
from the same species. The confocal images were acquired
using an LSM 710 Meta confocal microscope (Zeiss). For
dual-color staining, images were acquired sequentially to
avoid dye interference. ImageJ software was used for post-
processing of the images, eg, scaling, merging, and co-
localization analysis.
Glomerular Isolation
Mice were anesthetized and perfused by infusing the abdom-
inal artery with 5 mL of phosphate-buffered saline containing
8 107 Dynabeads M-450 beads (Dynal Biotech ASA, Oslo,
Norway). After perfusion, the kidneys were removed, minced
into 1-mm3 pieces, and digested in collagenase A, and the
glomeruli-containing Dynabeads were collected using a
magnetic particle concentrator as described previously.37
Transmission Electron Microscopy
For transmission electron microscopy, kidney cortical tis-
sues were cut into small pieces (1 mm3), ﬁxed with 2.5%
glutaraldehyde, and embedded in Epon 812 (Polysciences
Inc., Warrington, PA). Conventional electron micrographs
were obtained using an EM-10 microscope (Zeiss) operated
at 60 kV. The podocyte foot process density was estimated
by dividing the total length of glomerular basement mem-
brane by the total number of foot processes present in each
micrograph.
Statistical Analysis
For immunoblot analysis, bands were scanned and the inte-
grated pixel density was determined using a densitometer and
the ImageJ analysis program. All in vitro studies and
immunoblot analyses were performed with triplicate samples
and were repeated three to six times. All the data are
expressed as means  SD or as otherwise indicated. Statis-
tical analysis of the data from multiple groups was performed
by analysis of variance followed by Student-NewmaneKeulsajp.amjpathol.org - The American Journal of Pathology
GSK3b Regulates Podocyte FA Dynamicstests. Data from two groups were compared by Student’s
t-test or Wilcoxon rank sum test. Linear regression analysis
was applied to examine possible relationships between two
parameters. P < 0.05 was considered signiﬁcant.Figure 1 Lithium treatment abrogates Adriamycin (ADR; doxorubicin)-
elicited podocyte hypermotility as assessed by cell migration assay. A:
Differentiated podocytes were stimulated with 0.25 mg/mL of ADR or an equal
volume of vehicle 6 hours after pretreatment with 10 mmol/L lithium chloride
(LiCl) or 10 mmol/L sodium chloride (NaCl), and subsequently scratch was
processed using a 10-mL pipette. Control cells were treated with NaCl and
vehicle. The observation was made immediately after scratch (0:00 hour) and
at 24:00 hours. B: Quantiﬁcation of the cell migration area by computerized
morphometric analysis. Data are given as means  SD. n Z 20 areas from
three independent experiments. *P < 0.05 versus all other groups; yP < 0.05
versus sodium treatment alone. Original magniﬁcation, 200.
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Lithium Abrogates Podocyte Hypermotility Induced by
Doxorubicin Stimulation
The conditionally immortalized differentiated murine podo-
cytes in culture exhibited typical arborized morphologic
features and were characterized as expressing multiple
podocyte markers (Supplemental Figure S1). Evidence sug-
gests that podocytes are motile cells with considerable
constitutive motility.38 Indeed, as revealed by a traditional
cell migration assay for assessing cellular motility, podocytes
under basal conditions possessed a substantial migratory ca-
pacity that lessened the distances between the leading edges
of the migrating podocyte sheets. Cells were pretreated with
lithium or sodium for 6 hours, followed by doxorubicin injury
or vehicle treatment. The basal migrating activity of podocytes
was relatively reduced by lithium treatment alone but was
unaffected by sodium treatment. In contrast, doxorubicin-
injured podocytes demonstrated strikingly accelerated
closure of the gap between the invading fronts of the cells,
suggesting enhanced podocyte motility. This effect of doxo-
rubicin was markedly abrogated by lithium treatment
(Figure 1A). These morphologic ﬁndings were further
corroborated by quantitative measurements of cell migration
area (Figure 1B). In addition to rectifying hypermotility,
lithium also seemed to elevate the expression of podocyte
markers, such as nephrin, in the conditionally immortalized
differentiated murine podocytes (Supplemental Figure S1).
Lithium Preserves FA and Actin Cytoskeleton Integrity
in Doxorubicin-Injured Podocytes
FA turnover is a prerequisite for cell spreading and migration;
accordingly, FA dynamics has been implicated in the control
of cellular motility.15 To understand whether the effects of
doxorubicin and lithium on podocyte motility were associated
with alterations in FA and the ensuing changes in actin cyto-
skeleton, podocytes were subjected to phalloidin labeling for
F-actin and to immunoﬂuorescence staining for paxillin, a core
structural component of FA. Differentiated podocytes either
under normal conditions or after vehicle treatment demon-
strated abundant FAs that were located at the cell edges,
accompanied by intense phalloidin-labeled ventral stress ﬁbers
that were anchored to FAs at both ends (Figure 2A). The
nuclear staining of paxillin was seemingly nonspeciﬁc because
it was also probed in the negative control staining, where the
primary antibody was replaced with preimmune IgG
(Figure 2A). Lithium treatment alone slightly reduced the
number of FAs but barely affected the size of FAs, suggesting
a stabilized FA. Correspondingly, lithium aloneetreated
podocytes exhibited a stretched cellular shape and a ventral
stress ﬁber with long paralleled cortical stress ﬁbers as major
F-actin that were indistinguishable from the morphologic fea-
tures of control podocytes. In contrast, in doxorubicin-injured
podocytes, the number of FAs was substantially increased,2745
Figure 2 Lithium preserves FAs and actin cytoskeleton integrity in Adriamycin (ADR; doxorubicin)-injured podocytes. Differentiated podocytes were
stimulated with 0.25 mg/mL of ADR or an equal volume of vehicle 6 hours after pretreatment with 10 mmol/L lithium chloride (LiCl) or 10 mmol/L sodium
chloride (NaCl). Eight hours later, cells were ﬁxed and subjected to double staining for cytoskeletal F-actin with rhodamine phalloidin and paxillin, an FA
marker. A: Control podocytes displayed evident FAs located at the cell edges associated with intense phalloidin-labeled ventral stress ﬁbers anchored to FAs at
both ends. Lithium aloneetreated podocytes demonstrated slightly fewer FAs, a more stretched cellular shape, and ventral stress ﬁbers with long paralleled
cortical stress ﬁbers similar to the morphologic features of control podocytes. In contrast, ADR-injured podocytes had an increased number of small FAs and
displayed an asterlike cell shape as well as actin cytoskeleton disruption that manifested as increased expression of cortical actin ﬁlaments, drastically
diminished ventral stress ﬁbers, more transverse arcs, and sporadic short dorsal stress ﬁbers connected to the FA at only one end. Lithium treatment prevented
the effect of ADR, restored the number and size of FAs, retained stress ﬁbers, and largely preserveed actin cystoskeleton integrity in podocytes. The staining of
paxillin in the nucleus was nonspeciﬁc because it was also noted in negative control, where the antipaxillin primary antibody was replaced with preimmune
IgG. Boxed regions in the paxillin images are shown at higher magniﬁcation. B: Computerized morphometric quantiﬁcation of FA size. ADR reduced the
average size of FAs from approximately 3 mm2 to <1 mm2, and this effect was obliterated by lithium pretreatment. C: Quantiﬁcation of the number of FAs per
podocyte. Lithium treatment alone reduced the number of FAs from 137 to approximately 71 per cell, whereas ADR increased FA number to approximately 275
per cell, and this effect was abrogated by lithium pretreatment. Data are given as means  SD. nZ 30 cells from three independent experiments. *P < 0.05
versus control; yP < 0.05 versus LiCl þ ADR. Scale bar Z 10 mm (A). Original magniﬁcation: 800 (boxed regions in A).
Xu et aland FAs dramatically shrunk to the size that was likely
tantamount to that of focal complexes or nascent adhesions,
denoting a more dynamic FA. In agreement, doxorubicin-
injured podocytes exhibited an asterlike cell shape and actin
cytoskeleton disruption that manifested as increased expres-
sion of cortical ﬁlaments, diminished ventral stress ﬁbers,
more transverse arcs, and sporadic short dorsal stress ﬁ-
bers that were connected to the FA only at one end. This
cytopathic effect is reminiscent of the actin changes that
are observed in foot process effacement in vivo in doxo-
rubicin podocytopathy.1e4 Lithium treatment strikingly
prevented the doxorubicin-induced increase in FA
numbers and shrinkage in FA sizes, retained stress ﬁbers,
and largely preserved actin cytoskeleton integrity. These
morphologic ﬁndings were subsequently corroborated by2746morphometric measurements of FA sizes and absolute FA
counts (Figure 2, B and C).
Lithium Normalizes the Doxorubicin-Accelerated
Dynamics of FA Turnover in Podocytes
Fixed podocytes provide only a brief snapshot of FA
expression. By observing alive podocytes, however, addi-
tional insights into FA dynamics could be gained to validate
or complement the ﬁndings from ﬁxed cells. To further
deﬁne the functional impact of lithium- and doxorubicin-
regulated FA numbers and sizes on FA dynamics, live
imaging of podocytes was performed. Green ﬂuorescent
proteineconjugated paxillin was ectopically expressed in
podocytes by transient transfection so that turnover of FAsajp.amjpathol.org - The American Journal of Pathology
Figure 3 Lithium corrects the Adriamycin (ADR;
doxorubicin)-accelerated dynamics of FA turnover
in podocytes. A: Differentiated podocytes were
transiently transfected with a vector encoding
green ﬂuorescent protein (GFP)epaxillin and were
subjected to time-lapse microscopy for 1 hour,
followed by ﬂuorescence immunocytochemical
staining for synaptopodin. Representative ﬂuores-
cent micrographs of synaptopodin staining showed
that podocytes retain the podocyte marker protein
synaptopodin. B: Podocytes transfected with GFP-
paxillin were injured with ADR for 8 hours after 10
mmol/L lithium chloride (LiCl) or 10 mmol/L sodium
chloride (NaCl) treatment for 6 hours. Subse-
quently, live podocytes were subjected to time-
lapse ﬂuorescence microscopy for 1 hour with 2
minutes between microscopic image frames. The
Detail column represents a series of time-lapse
microscopic image frames aligned to show the
temporal evolution of individual FAs from assembly
to disassembly in differently treated podocytes.
Because image frames were captured at a ﬁxed rate
(0.5 frames per minute), the number of image
frames showing the temporal evolution of an indi-
vidual FA accordingly correlated the FA dynamics.
Thus, hypodynamics and hyperdynamics of FA
turnover were indicated by more and less frames,
respectively. ADR-treated podocytes shrank rapidly,
as shown by the whole cell image and exhibit an
accelerated FA turnover (Detail column). This effect
was abrogated by lithium pretreatment. Boxed
regions focal adhesions, whose turnover is shown
in Detail column. C: Quantiﬁcation of FA assembly
rates. Lithium treatment alone slightly reduced the
assembly rate. ADR drastically increased the FA as-
sembly rate, which was signiﬁcantly obliterated by
lithium pretreatment. D: Quantiﬁcation of FA
disassembly rates. ADR markedly increased the FA
disassembly rate, and lithium pretreatment pre-
vented the effect. Horizontal bars indicate the
median values and the top and bottom lines of the
boxes indicate the 3rd and 1st quartile, respectively
(C and D). Data are given as medians  ranges (C
and D). nZ 30 cells from six experiments (C and D).
*P < 0.05 versus all other groups by Wilcoxon rank
sum test (C and D). Scale barZ 10 mm (A and B).
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Figure 4 Inhibitory phosphorylation of GSK3b is negatively associated with paxillin phosphorylation and activation in podocytes. A: Cell lysates were
prepared from treated differentiated podocytes at the indicated time points after Adriamycin (ADR; doxorubicin) injury and were subjected to Western blot
analysis. ADR injury reduced inhibitory phosphorylation of GSK3b but enhanced paxillin phosphorylation, whereas lithium chloride (LiCl), as a selective inhibitor
of GSK3b, counteracted this effect, potentiated GSK3b phosphorylation, and diminished paxillin phosphorylation at different time points. B: Densitometric
analysis of immunoblots quantiﬁed the relative levels of phosphorylated paxillin/total paxillin ratios and phosphorylated GSK3b/total GSK3b ratios at different
time points. C: Linear regression analysis showed a negative correlation between inhibitory phosphorylation of GSK3b and paxillin phosphorylation and activation
in podocytes. The correlation coefﬁcient r was 0.7739. White, gray, and black colors represent 2, 8, and 24 hours, respectively. Data are given as means  SD.
n Z 6 separate experiments (B); n Z 6 representative experiments (C). *P < 0.05 versus control; yP < 0.05 versus LiCl þ ADR.
Xu et alcould be visualized and documented by time-lapse ﬂuores-
cence microscopy. After transfection and time-lapse mi-
croscopy, control cells retained podocyte morphology and
evidently expressed typical podocyte marker molecules,
including synaptopodin (Figure 3A), suggesting that podo-
cytes were maintained in a healthy state. Consistent with a
constitutive motility, basal FA dynamics were evidently
noted in podocytes under normal conditions and were barely
affected by vehicle and sodium treatment (Figure 3B).
Doxorubicin injury substantially accelerated FA turnover, as
reﬂected by a reduced number of microscopic image frames
showing the temporal evolution of an individual FA
(Figure 3B). In contrast, lithium treatment resulted in more
stable FA dynamics and prominently counteracted the effect
of doxorubicin in the observed podocytes. Computerized
morphometric analysis of FA turnover rates revealed that
both assembly and disassembly rates of FA were signiﬁ-
cantly elevated in doxorubicin-injured cells. Concomitant
lithium treatment largely prevented the effect of doxorubicin
and normalized the FA assembly and disassembly rates to
the levels of normal podocytes (Figure 3, C and D).Lithium Obliterates Doxorubicin-Elicited GSK3b
Overactivity and Paxillin Hyperphosphorylation
Next we tested whether lithium counteracted the effect of
doxorubicin on FA turnover through a direct action on FA2748molecules, such as paxillin. Differentiated podocytes were
pretreated with lithium or sodium for 6 hours, followed by
doxorubicin injury or vehicle treatment. Inhibitory phos-
phorylation of GSK3b was evidently increased by lithium,
in agreement with the role of lithium as a speciﬁc inhibitor
of GSK3b (Figure 4A). Doxorubicin injury prominently
diminished GSK3b phosphorylation at all observed time
points, denoting GSK3b overactivity. This effect was largely
abrogated by lithium treatment. Paxillin phosphorylation, on
the contrary, exhibited opposing tendencies in response
to doxorubicin injury or lithium treatment: doxorubicin
enhanced whereas lithium abolished paxillin phosphoryla-
tion. Densitometric analysis of immunblots conﬁrmed these
ﬁndings and revealed an inverse correlation between the
changes in GSK3b phosphorylation and the changes in
paxillin phosphorylation (Figure 4, B and C).GSK3b Is Necessary and Sufﬁcient for Paxillin
Overactivation, FA Instability, and Podocyte
Hypermotility
To examine a possible causal relationship between GSK3b
and paxillin phosphorylation and activation as well as the
ensuing changes in FA dynamics and podocyte motility, the
activity of GSK3b was selectively manipulated by forced
expression of vectors encoding the hemagglutinin-
conjugated wild-type GSK3b, a dominant negative kinaseajp.amjpathol.org - The American Journal of Pathology
Figure 5 GSK3b regulates paxillin phosphory-
lation in podocytes and determines the ensuing FA
dynamics. A: Differentiated podocytes were trans-
fected with vectors encoding the hemagglutinin
(HA)-conjugated wild-type (WT) GSK3b or a domi-
nant negative KD or a constitutively active (S9A)
mutant of GSK3b. Cells were harvested 48 hours
after transfection, and cell lysates were subjected
to immunoblot analysis for phosphorylated (p)
paxillin, total paxillin, HA, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). B: Densito-
metric analysis of immunoblots quantiﬁed the
relative levels of p-paxillin/total paxillin ratios.
Cells were treated with 10 mmol/L lithium chloride
(LiCl) or 10 mmol/L sodium chloride (NaCl) for 6
hours before injury with vehicle or 0.25 mg/mL of
Adriamycin (ADR; doxorubicin). C: Podocytes were
ﬁxed 8 hours after injury and were subjected to
phalloidin labeling of F-actin (red) and immuno-
ﬂuorescence staining for paxillin (green). Forced
expression of KD diminished the ADR-elicited
podocyte injury, marked by an increased number
and reduced size of FAs as well as actin cytoskeleton
disorganization that manifests as increased
expression of cortical ﬁlaments and diminished
stress ﬁbers, reminiscent of the protective effect of
lithium. In contrast, ectopic expression of S9A
prominently increased the number and reduced the
size of FAs and disrupted actin cytoskeleton
integrity under basal conditions, mimicking the
effect of ADR injury. On ADR injury, the protective
effect of lithium on FAs and actin cytoskeleton was
largely abolished in cells expressing S9A. Arrow-
heads indicate representative FAs. D: FA number
quantiﬁcation by computerized morphometric
analysis. E: Computerized morphometric analysis of
the size of FAs. F: Number and size quantiﬁcation of
FAs in ADR-injured podocytes after lithium treat-
ment (Figure 2A) or in ADR-injured KD-expressing
podocytes (Figure 5C) by computerized morpho-
metric analysis; not statistically signiﬁcant be-
tween the two groups. Data are given as means 
SD. nZ 6 representative experiments (B); nZ 25
cells, three independent experiments (DeF).
*P < 0.05 versus all other groups (B) or versus
vehicle treated WT-expressing cells (D and E);
yP < 0.05 versus ADR-injured WT-expressing cells
(D and E), zP < 0.05 versus ADR-injured and LiCl-
treated WT-expressing cells (D and E). Scale
barZ 5 mm (C).
GSK3b Regulates Podocyte FA Dynamicsdead mutant (KD) or a constitutively active mutant (S9A) of
GSK3b. Immunoﬂuorescence staining for hemagglutinin
revealed a satisfactory transfection efﬁciency (>70%).
Forced expression of KD reduced paxillin phosphorylation
(Figure 5, A and B) and diminished the doxorubicin-elicited
podocyte injury, marked by an increased number and
reduced size of FAs as well as actin cytoskeleton disorga-
nization that manifested as increased expression of cortical
ﬁlaments and diminished stress ﬁbers, reminiscent of theThe American Journal of Pathology - ajp.amjpathol.orgprotective effect of lithium (Figure 5, CeE). In contrast,
ectopic expression of S9A prominently elicited hyper-
phosphorylation and overactivation of paxillin (Figure 5, A
and B) under basal conditions, associated with an increased
number and reduced size of FAs as well as disruption of actin
cytoskeleton integrity, mimicking the effect of doxorubicin
(Figure 5, CeE). Moreover, on doxorubicin injury, the pro-
tective effect of lithium on FAs and actin cytoskeleton was
largely abolished in cells expressing S9A (Figure 5, CeE),2749
Figure 6 Modulation of GSK3b activity affects podocyte motility. Differentiated podocytes were transfected with vectors encoding the hemagglutinin (HA)-
conjugated wild-type (WT), a dominant negative KD, or a constitutively active (S9A) mutant of GSK3b and then were treated with 10 mmol/L lithium chloride
(LiCl) or 10 mmol/L sodium chloride (NaCl) for 6 hours before injury with vehicle or 0.25 mg/mL of Adriamycin (ADR; doxorubicin). Cells were then subjected to
cell migration assay for the indicated time. Cell migration assay of podocytes transfected with WT or KD (A) or with WT or S9A (B) after the indicated treatments.
Quantiﬁcation of the cell migration area of podocytes transfected with WT or KD (C) or with WT or S9A (D) after the indicated treatments by computerized
morphometric analysis. E: Quantiﬁcation of the cell migration assay of ADR-injured podocytes after lithium treatment (Figure 1A) or ADR-injured KD-expressing
podocytes from A by computerized morphometric analysis; not statistically signiﬁcant between the two groups. Data are given as means SD. nZ 20 areas from
three independent experiments (C and E); nZ 6 areas, three independent experiments (D). *P < 0.05 versus vehicle-treated WT-expressing cells (C and D);
yP < 0.05 versus ADR-injured KD-expressing cells (C) or versus ADR- and LiCl-treated S9A-expressing cells (D). Original magniﬁcation, 200 (A and B).
Xu et alsuggesting that inhibitory phosphorylation of GSK3b is, at
least in part, responsible for the protection conferred by
lithium. Consistently, on doxorubicin injury, lithium-treated
podocytes and KD-overexpressing podocytes displayed
comparable numbers and sizes of FAs (Figure 5F). Consistent
with the role of FA and actin cytoskeleton in cellular motility,
forced expression of S9A reinforced, whereas ectopic
expression of KD mitigated, the doxorubicin-accelerated
closure of the gap between the leading edges of the2750migrating podocyte sheets as assessed by the cell migration
assay, thus inferring enhanced and impeded podocytemotility,
respectively (Figure 6, AeD). Moreover, the suppressive ef-
fect of lithium on doxorubicin-elicited cell migration was
substantially abrogated in S9A-overexpressing podocytes
injuredwith doxorubicin (Figure 6,B andD), again suggesting
that GSK3b inhibition is an indispensable and keymechanism
accounting for the effect of lithium on podocyte motility.
Consistently, lithium-treated podocytes andKD-overexpressingajp.amjpathol.org - The American Journal of Pathology
Figure 7 Paxillin interacts with GSK3b as its putative substrate in podocytes. A: Differentiated podocytes were ﬁxed and subjected to dual-color immu-
nocytochemical staining for GSK3b (green) and paxillin (red). A high-powered view of normal podocytes by confocal ﬂuorescence microscopy revealed a close
spatial association and co-localization (arrowheads) between a discrete pool of GSK3b and paxillin in the xy and z planes. B: Lysates of cultured podocytes and
homogenates of glomeruli isolated from normal murine kidneys by the magnetic beadsebased approach were subjected to immunoprecipitation (IP) assay by
using an anti-GSK3b antibody or the preimmune IgG. Subsequently, immunoprecipitates were processed for immunoblot analysis for paxillin. Arrow indicates the
band for paxillin. C: In silico analysis demonstrated that amino acid residues S126, S226, S328, and S336 of paxillin reside in the consensus motifs for phos-
phorylation by GSK3b, denoting paxillin as a cognate substrate for GSK3b. D: Characteristics of consensus GSK3b phosphorylation motifs, including the predicted
phosphorylation sites, prediction conﬁdence scores, and sequences in paxillin, as estimated by in silico analysis. Scale barZ 5 mm (A). IB, immunoblot.
GSK3b Regulates Podocyte FA Dynamicspodocytes displayed comparable migration activity on doxoru-
bicin injury (Figure 6E).
Paxillin Co-Localizes and Physically Interacts with
GSK3b as Its Putative Substrate in Podocytes
To further decipher the mechanistic essence of the GSK3b-
mediated regulation of paxillin phosphorylation and acti-
vation, the subcellular physical association between GSK3b
and paxillin was examined by dual-color ﬂuorescence
immunocytochemical staining. A high-powered view of
normal podocytes by confocal ﬂuorescence microscopy
revealed a close spatial association and co-localization be-
tween a discrete pool of GSK3b and paxillin in the xy and z
planes (Figure 7A). To validate this morphologic observa-
tion, immunoprecipitation was performed and demonstrated
that GSK3b evidently coprecipitated with paxillin in lysates
of cultured podocytes and in homogenates of glomeruli
isolated from murine kidneys, suggesting that GSK3b
physically interacts with paxillin in podocytes in vivo and
in vitro (Figure 7B). To further deﬁne the mechanism by
which GSK3b regulates paxillin phosphorylation, the amino
acid sequences of paxillin (UniProtKB/Swiss-Prot accession
number Q8VI36.1) were subjected to computational active
site analysis (http://scansite.mit.edu/motifscan_seq.phtml,
last accessed December 28, 2013) for putative consensus
phosphorylation motifs for GSK3b. In silico analysis
deduced that residues S126, S226, S328, and S336 of
paxillin reside in the consensus motifs for phosphorylation
by GSK3b, with prediction scores higher than 0.5 denotingThe American Journal of Pathology - ajp.amjpathol.orghigh-conﬁdence matches to GSK3b phosphorylation motifs
(Figure 7, C and D). Collectively, these data suggest that
paxillin is a putative cognate substrate for GSK3b.A Single Low Dose of Lithium Ameliorates Podocyte
Foot Process Effacement, Attenuates Proteinuria, and
Improves Glomerulosclerosis in Experimental
Doxorubicin Nephropathy
To further explore whether the GSK3b-regulated FA dy-
namics are involved in podocytopathy in vivo and also to
assess the possible effect of therapeutic targeting of GSK3b, we
used the mouse model of doxorubicin nephropathy, which is
accounted for, in part, by podocyte hypermotility and re-
capitulates key features of podocytopathy and focal and
segmental glomerulosclerosis in humans, including podocyte
foot process effacement, massive proteinuria, and progressive
glomerulosclerosis.39,40 Mice were injured with an intravenous
injection of 10mg/kg doxorubicin 6 hours after an i.p. injection
of a low dose of 40mg/kg of lithium chloride or an equal molar
amount (1 mEq/kg) of sodium chloride saline. Doxorubicin
injury elicited heavy proteinuria that peaked on days 5 and 7
and then partially receded on day 14 as determined by urine
electrophoresis and urine albumin/creatinine ratios (Figure 8, A
and B) and was associated with progressive glomerulosclerosis
on periodic acideSchiff staining and with extensive foot pro-
cess effacement on electron microscopy (Figure 8, C and D).
Lithium therapy considerably attenuated proteinuria, amelio-
rated glomerulosclerosis, and substantially improved foot2751
Figure 8 Lithium attenuates podocyte effacement and ameliorates proteinuria and progressive glomerulosclerosis in experimental Adriamycin (ADR;
doxorubicin) nephropathy. A: Mice were injured with ADR or an equal volume of vehicle 6 hours after a single i.p. injection of 40 mg/kg of lithium chloride
(LiCl) or an equal molar amount (1 mEq/kg) of sodium chloride as saline. Urine was collected at the indicated time points and was subjected to SDS-PAGE and
staining with Coomassie Brilliant Blue. Bovine serum albumin (BSA), 5, 10, 20, and 40 mg, served as standard control. Urine samples (1.5 mL) collected on the
indicated postinjury days from each group were loaded. B: Quantiﬁcation of urine albumin levels adjusted with urine creatinine concentrations. C: Repre-
sentative micrographs demonstrated periodic acideSchiff staining mouse kidneys. ADR-induced injury was featured by glomerular matrix accumulation and
protein casts. D: Electron microscopy of kidney specimens procured from animals on day 7. Podocyte injury featured by extensive foot process effacement is
evident in ADR-treated kidney, and lithium therapy signiﬁcantly attenuates this lesion. E: Morphometric analysis of glomerulosclerosis scores on kidney
sections prepared on day 14. F: Absolute count of the number of foot processes per unit length of glomerular basement membrane (GBM) on electron mi-
crographs of kidney specimens. Data are given as means  SD. nZ 6 (B, E, and F). *P < 0.05 versus control group (B, E, and F); yP < 0.05 versus LiCl þ ADR
(B, E, and F). Scale bars: 20 mm (C); 2 mm (D).
Xu et al
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Figure 9 Lithium counteracts the Adriamycin
(ADR; doxorubicin)-induced GSK3b overactivity and
paxillin hyperphosphorylation in glomeruli and re-
instates actin cytoskeleton integrity in glomerular
podocytes. A: Glomeruli were isolated from kidneys
from differently treated animals by the magnetic
beadsebased approach and were homogenized for
immunoblot analysis for phosphorylated GSK3b,
phosphorylated paxillin, total GSK3b, total paxillin,
and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). B: Densitometric Western blot analysis
estimates the relative levels of phosphorylated
GSK3b/total GSK3b ratios and phosphorylated pax-
illin/total paxillin ratios in isolated glomeruli from
different groups. C: Frozen kidney sections procured
on day 14 were subjected to phalloidin labeling of F-
actin (red) as well as immunoﬂuorescence staining
for synaptopodin (green), a podocyte marker.
Confocal microscopy images. ADR injury not only
reduces synaptopodin expression but also di-
minishes the integrated pixel density of the merged
areas (yellow), where F-actin co-localizes with syn-
aptopodin, suggesting a disorganized actin cyto-
skeletal network in the remnant intact podocytes.
Computerized morphometric analysis of the ratios of
integrated pixel densities between yellow signal to
green signal in immunoﬂuorescence micrographs
obtained in C and D. Data are given as means SD.
nZ 6 (B and D). *P< 0.05 versus control group (B)
or versus all other groups (D); yP < 0.05 versus LiCl
þ ADR (B). Scale barZ 20 mm (C).
GSK3b Regulates Podocyte FA Dynamicsprocess effacement in doxorubicin-injured mice, consistent
with a podocyte protective and antiproteinuric effect. Control
mice were treated with sodium or lithium 6 hours before
vehicle injection, and no noticeable changes in proteinuria or
renal histologic features were noted. These morphologic ﬁnd-
ings were further corroborated by the semiquantitative
morphometric measurements of glomerulosclerosis scores and
the absolute count of the number of foot processes per unit
length of glomerular basement membrane (Figure 8, E and F).
Lithium Mitigates GSK3b Overactivity, Prevents
Paxillin Activation, and Reinstates Actin Cytoskeleton
Integrity in Doxorubicin-Injured Glomeruli
To examine the molecular changes associated with the
lithium-induced remission of proteinuria, glomeruli were
isolated from kidneys by themagnetic beadsebased approach
and were homogenized for immunoblot analysis. Lithium
treatment substantially enhanced the inhibitory phosphory-
lation of GSK3b, suggestive of repressed GSK3b activity,
concomitant with diminished phosphorylation of paxillin
(Figure 9, A and B). In contrast, doxorubicin injury signiﬁ-
cantly enhanced the activity of GSK3b, as marked by the
reduced inhibitory phosphorylation of GSK3b associated
with accentuated phosphorylation of paxillin on all observed
time points. This effect was largely abolished by lithium
treatment. To examine the effect of lithium on the ensuing
actin cytoskeleton organization, kidney specimens procuredThe American Journal of Pathology - ajp.amjpathol.orgfrom animals on day 14 were subjected to phalloidin labeling
for F-actin and to immunoﬂuorescence staining for synapto-
podin, a podocyte marker (Figure 9C). Confocal ﬂuorescence
microscopy demonstrated that intense F-actin was found to
locate extensively to all over the glomerular tufts in normal
kidneys. Podocyte expression of F-actin was highlighted by
co-localization of F-actin signals (red) with synaptopodin
staining (green). Lithium treatment alone barely affected
either F-actin expression or synaptopodin expression in
glomeruli and podocytes. In contrast, doxorubicin induced
prominent podocyte injury, as evidenced by reduced syn-
aptopodin expression, and also diminished F-actin expression
in the periphery of glomerular tufts, consistent with podocyte
localization. In agreement, the co-localization of F-actin with
synaptopodin was considerably lessened in doxorubicin-
injured kidneys, suggestive of a disorganized actin cytoskel-
etal network in the remnant intact podocytes. Lithium therapy
largely abrogated this injurious effect of doxorubicin, pre-
vented the reduction in synaptopodin expression, and rein-
stated F-actin and synaptopodin coexpression in podocytes
(Figure 9D).
Discussion
A growing body of evidence indicates that podocytes are
motile cells and that podocyte foot process motility is vital
for maintaining the structural and functional homeostasis of
the glomerular ﬁltration barrier.1,5,6 FAs, by which cells are2753
Figure 10 Schematic diagram detailing the mechanism of the GSK3b-
governed FA dynamics in the pathogenesis of podocytopathy. GSK3b plays a
key role in the regulation of FA turnover and podocyte motility by directing
paxillin phosphorylation and activation and subsequently controlling actin
cytoskeleton dynamics. As a redox-sensitive signaling transducer, the ac-
tivity of GSK3b could be reinforced on oxidative stress induced by a variety of
podocyte-injurious mediators, including Adriamycin (doxorubicin). GSK3b
overactivity will elicit paxillin hyperphosphorylation and overactivation and
thus cause the ensuing actin cytoskeleton disorganization and podocyte
hypermotility, ultimately resulting in podocyte foot process effacement,
massive proteinuria, and progressive glomerulosclerosis. GSK3b is a drug-
gable target that could be blocked by lithium, a selective inhibitor of GSK3b
and US Food and Drug Administrationeapproved mood stabilizer that has
been safely used for>50 years as a ﬁrst-line therapy for affective psychiatric
disorders. Lithium treatment could override the Adriamycin-elicited GSK3b
overactivity, counteract paxillin hyperphosphorylation and overactivation,
and thereby obliterate podocyte hypermotility and reinstate actin cyto-
skeleton integrity. Consequently, lithium therapy could ameliorate the
Adriamycin-induced podocyte foot process effacement, induce proteinuria
remission, and improve glomerulosclerosis.
Xu et alanchored to the extracellular matrix, are a major determinant
of actin cytoskeleton dynamics and cellular motility.15 Thus,
high FA turnover is associated with high motility of cells.20
To our knowledge, the present study is the ﬁrst attempt to
explore the GSK3b-controlled FA turnover and the ensuing
effects on actin cytoskeleton organization and cell motility
in podocytes (Figure 10). We demonstrated that lithium, a
selective GSK3b inhibitor, protected podocytes from doxo-
rubicin injury in vitro and in vivo. Although a variety of other
mechanisms might also contribute, it seems that lithium
conferred this podocyte protective action, at least in part, by
counteracting the doxorubicin-elicited GSK3b overactivity;
intercepting the GSK3b-directed hyperphosphorylation and
overactivation of paxillin, a core structural component of
FAs; and subsequently impeding FA turnover and overriding
podocyte hypermotility (Figure 10).
GSK3b situates at the nexus ofmultiple crucial cell signaling
pathways and is centrally involved in the pathogenesis of dis-
ease in multifaceted organ systems, including the kidney.41 As
a redox-sensitive signaling transducer, the activity of GSK3b
could be substantially enhanced on oxidative stress induced by
a multitude of podocyte-injurious mediators, such as doxoru-
bicin and chronic kidney injuries.42We recently uncovered that
expression of GSK3b is aberrantly up-regulated in diseased
human kidneys in tubules and glomeruli.43 Similarly, Waters
and Koziell44 also noted up-regulation of GSK3b in human
podocytes in association with speciﬁc NPHS1 mutations.
Consistently, gene-targeted knock-in mice with mutated
uninhibitable GSK3 developed albuminuria and podocyte
injury, suggesting a detrimental role of GSK3 in podocyte
injury.45 In contrast, studies exploiting selective small mole-
cule inhibitors of GSK3b reached conﬂicting conclusions. For
example, inhibition of GSK3b by the selective small molecule
inhibitor 6-bromoindirubin-30-oxime (BIO) at a low dose
dramatically normalized proteinuria and attenuated histologic
injury of glomeruli in rat models of diabetic nephropathy,
although hyperglycemia was not corrected, implying direct
antiproteinuric and renoprotective action.46 However, Matsui
et al47 found that high-dose BIO exacerbated proteinuria and
loss of glomerular nephrin in puromycin-injured rats. Another
study by Dai et al48 reported that a transient and low level of
proteinuria followed by a rapid spontaneous remission was
provoked by an ultrahigh dose of lithium chloride (16 mmol/
kg),which is almost two times themedian lethal dose of lithium
chloride in mice. In contrast, we demonstrated that low-dose
lithium conferred prominent protection against podocyte
injury. Of note, as typical chemical inhibitors of kinases,
GSK3b blockers, including lithium, BIO, and 4-benzyl-2-
methyl-1,2,4-thiadiazolidine-3,5-dione, if used at high doses,
could have nonselective off-target effects and could induce
cytotoxicity and even lethality.49 Thus, the most likely expla-
nation for these conﬂicting ﬁndings might be the difference in
the doses of GSK3b inhibitor. Collectively, accumulating ev-
idence indicates that GSK3b promotes podocyte injury and
proteinuria, and inhibition of GSK3b by low-dose inhibitors
might be beneﬁcial for podocytopathy.2754Lithium, a selective inhibitor of GSK3b, has been
commonly and safely used for the past 50 years as a US Food
and Drug Administrationeapproved ﬁrst-line drug to treat
bipolar affective disorders.50,51 Recent evidence revealed
that blockade of GSK3b by lithium reduces cellular motility
in a variety of cells, including vascular smooth muscle
cells,26 glioma cells,27 gastric cancer cells,28 and airway
epithelial cells,52 suggesting that lithium might be a choice of
therapy for diseases associated with cellular hypermotility,ajp.amjpathol.org - The American Journal of Pathology
GSK3b Regulates Podocyte FA Dynamicssuch as malignant tumor metastasis. Podocyte hypermotility
is a central pathogenic mechanism accounting for nephrotic
glomerulopathy induced by a variety of mediators, including
soluble urokinase-type plasminogen activator receptor,12
proteases, and nephrotoxins such as doxorubicin.9,10
Correction of podocyte hypermotility via therapeutic target-
ing of FA dynamics, a prerequisite of cell migration and
motility, has been shown to successfully override podocyte
injuries induced by podocytopathic mediators and to
improve the podocyte structure and function.23 In this study,
lithium, through stabilizing FA dynamics, also counteracted
doxorubicin-elicited podocyte hypermotility and consis-
tently resulted in a podocyte-protective and antiproteinuric
effect in doxorubicin nephropathy. Apparently, this study
might have an immediate implication for clinical translation
into prophylactic treatment for recurrent focal and segmental
glomerulosclerosis in kidney transplant patients, which has
been attributed to a rapid podocytic injury associated with
podocyte hypermotility caused by circulating permeability
factors, such as soluble urokinase-type plasminogen acti-
vator receptor.12,53
Of note, a basal level of podocyte motility is essential for
sustaining the glomerular ﬁltration barrier homeostasis.
Podocyte motility that is too low secondary to genetic de-
fects of cytoskeleton structural or regulatory molecules has
been associated with cytopathic changes in podocytes that
ultimately also result in focal and segmental glomerulo-
sclerosis.1 Therefore, provided the observation that the
lithium represses FA turnover and podocyte motility in
normal podocytes, one of the conceivable concerns would
be the potential podocytopathic effect of lithium therapy.
Indeed, long-term lithium therapy primarily for psychiatric
disorders has been complicated by some renal adverse ef-
fects, such as nephrotic syndrome, glomerular disease, and
interstitial nephritis, as reported by Markowitz et al54 in a
case series report. However, according to a large-scale
epidemiology study,55 the incidence of chronic kidney dis-
ease in lithium-treated patients is actually comparable with
that in the general population, suggesting that the lithium-
associated renal adverse effects are uncommon. Further-
more, patients with lithium-associated kidney diseases
usually have received lithium therapy at the psychiatric high
dose for a long time (usually >10 years). In the present
study, the single dose of lithium used (40 mg/kg) is much
lower than the standard dose of lithium that has been safely
and routinely used for neurobiology research (120 mg/kg) in
rodents, and no detectable changes in glomerular histologic
features or function were observed in control mice, sug-
gesting that low-dose lithium might be protective for
podocyte injury. Therefore, it seems that short-term use of
low-dose lithium is safe in humans and might be a prom-
ising approach for preventing podocytopathies.
In summary, GSK3b plays an important role in the regula-
tion of FA turnover and podocyte motility by directing paxillin
phosphorylation and activation and subsequently controlling
actin cytoskeleton dynamics. Lithium, an inhibitor of GSK3b,The American Journal of Pathology - ajp.amjpathol.orgattenuated the doxorubicin-elicited paxillin phosphorylation
and rapid FA turnover, reinstated actin cytoskeleton integrity,
and overrode podocyte hypermotility. In experimental doxo-
rubicin nephropathy, a single low dose of lithium effectively
suppressed the overactivity of GSK3b and paxillin, recovered
actin cytoskeleton in glomerular podocytes, prevented podo-
cyte foot process effacement, and attenuated proteinuria
(Figure 10). Collectively, this study suggests that the GSK3b-
governed FA dynamics might serve as a novel therapeutic
target for podocytopathy.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.06.027.References
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